Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01592968 · ClinicalTrials.gov registry record · Phase 3

Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases

A Phase 3 study of Metastatic Malignant Neoplasm in the Brain and Metastatic Malignant Neoplasm, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 3
Development phase
88
Enrollment target
1
Study location

NCT01592968 is a Phase 3 study of Metastatic Malignant Neoplasm in the Brain and Metastatic Malignant Neoplasm that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 88 participants, roughly in line with the 86-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01592968, a Phase 3 study of Metastatic Malignant Neoplasm in the Brain and Metastatic Malignant Neoplasm, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
88 participants
Enrollment target
1
Study location

Study Summary

This randomized phase III clinical trial compares stereotactic radiosurgery with whole brain radiation therapy to see how well they work in treating patients with non-melanoma cancer that has recently spread from the first location to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic radiosurgery is a specialized type of radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Whole brain radiation therapy delivers a lower dose of radiation to the entire brain over several treatments. It is not yet known whether stereotactic radiosurgery works better than whole brain radiation therapy in treating patients with non-melanoma brain metastases. Stereotactic radiosurgery may also cause fewer thinking and memory problems than whole brain radiation therapy.

Interventions

  • OTHER Quality-of-Life Assessment
  • RADIATION Stereotactic Radiosurgery
  • OTHER Cognitive Assessment
  • RADIATION Whole-Brain Radiotherapy

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 88 participants
Start Date 2012-08-02
Est. Completion 2027-09-30
Phase Phase 3

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT01592968

The ClinicalTrials.gov registry entry for NCT01592968 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 86-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Malignant Neoplasm in the Brain appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.

NCT01592968 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01592968 about?

NCT01592968 is a clinical study titled "Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases". This randomized phase III clinical trial compares stereotactic radiosurgery with whole brain radiation therapy to see how well they work in treating patients with non-melanoma cancer that has recently spread from the first location to the brain. Radiation therapy uses high energy x-rays to kill tumo...

What is the current status of trial NCT01592968?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 88 participants. The study started on 2012-08-02. Estimated completion is 2027-09-30.

What conditions does trial NCT01592968 study?

This clinical trial studies the following conditions: Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm.

What interventions are being tested in trial NCT01592968?

The interventions under investigation include: Quality-of-Life Assessment (OTHER), Stereotactic Radiosurgery (RADIATION), Cognitive Assessment (OTHER), Whole-Brain Radiotherapy (RADIATION).

Who is sponsoring clinical trial NCT01592968?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01592968 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metastatic Malignant Neoplasm in the Brain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.